Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ensartinib adjuvant therapy in resected ALK-positive stage II–IIIB NSCLC
ChiCTR2300070192Phase 2Not yet recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ensartinib in ALK-positive non-small cell lung cancer, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: 3-year disease-free survival rate. Planned start May 2023; status: not yet recruiting.
02
Drugs
ensartinib
03
Conditions
ALK-positive non-small cell lung cancer
Beyond the preview
Go deeper on ChiCTR2300070192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300070192.